CD34+ acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness genes and can be targeted by the BCL2 inhibitor venetoclax

• Katharina Mattes,
• Mylène Gerritsen,
• Hendrik Folkerts,
• Marjan Geugien,
• Fiona A. van den Heuvel,
• Arthur Flohr Svendsen,
• Guoqiang Yi,
• Joost H.A. Martens,
• Edo Vellenga

Affiliations

Katharina Mattes

Department of Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen

Mylène Gerritsen

Department of Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen

Hendrik Folkerts

Department of Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen

Marjan Geugien

Department of Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen

Fiona A. van den Heuvel

Department of Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen

Arthur Flohr Svendsen

Laboratory of Ageing Biology and Stem Cells, European Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Groningen

Guoqiang Yi

Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, the Netherlands

Joost H.A. Martens

Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, the Netherlands

Edo Vellenga

Department of Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen